Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp online chat

	NCI Highlights


	Maintenance Rituximab for Follicular Lymphoma Azacitidine Improves Survival in MDS Second Stem Cell Transplant Not Helpful in Myeloma

Phase I-II Chemotherapy with Cyclocytidine for Refractory Acute Leukemia, Lymphomas and Solid Tumors in Children

Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Trial Contact Information

Basic Trial Information

Phase Type Status Age Sponsor Protocol IDs
Phase II, Phase I Treatment Closed under 21 NCI POG-7516

Objectives

I.  Determine the response rate and toxicity of intermittent cyclocytidine 
administered to children with acute leukemia, lymphomas and solid tumors which 
are refractory to conventional and antineoplastic agents.
II.  Determine the maintenance potential of cyclocytidine in childhood 
leukemia with emphasis on the feasibility of use as a depot form of cytosine 
arabinoside.

Entry Criteria

Disease Characteristics:

See General Eligibility Criteria

Patient Characteristics:

See General Eligibility Criteria

General Eligibility Criteria:

Patients who are under 21 years of 
age at diagnosis with acute lymphocytic leukemia in relapse, acute 
granulocytic leukemia in relapse and solid tumors in relapse including Wilms' 
tumor, rhabdomyosarcoma, Ewing's sarcoma, osteosarcoma, neuroblastoma, 
retinoblastoma and brain tumors.  Patients with resistant leukemia must have 
evidence of relapse.

Expected Enrollment

Protocol closed 09/77.

Outline

Nonrandomized study.
Single-Agent Chemotherapy.  Cyclocytidine, CYC, NSC-145668.

Trial Contact Information

Trial Lead Organizations

Pediatric Oncology Group

Teresa Vietti, MD, Protocol chair
Ph: 314-454-6209

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.